In 2025, Farxigo, Tagrisso, and Imfinzi were the three major products of AstraZeneca. The company reported a sales share of about 37 percent in 2025, an increase in comparison to the previous year.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆÆ½â°æ can support your business.
U.S. Securities and Exchange Commission, & AstraZeneca. (February 18, 2026). Sales share of AstraZeneca's three major drugs from 2021 to 2025 [Graph]. In ÌÇÐÄÆÆ½â°æ. Retrieved July 23, 2026, from /statistics/1660807/astrazeneca-three-major-drug-sales-share/
U.S. Securities and Exchange Commission, und AstraZeneca. "Sales share of AstraZeneca's three major drugs from 2021 to 2025 ." Chart. February 18, 2026. ÌÇÐÄÆÆ½â°æ. Accessed July 23, 2026. /statistics/1660807/astrazeneca-three-major-drug-sales-share/
U.S. Securities and Exchange Commission, AstraZeneca. (2026). Sales share of AstraZeneca's three major drugs from 2021 to 2025 . ÌÇÐÄÆÆ½â°æ. ÌÇÐÄÆÆ½â°æ Inc.. Accessed: July 23, 2026. /statistics/1660807/astrazeneca-three-major-drug-sales-share/
U.S. Securities and Exchange Commission, and AstraZeneca. "Sales Share of Astrazeneca's Three Major Drugs from 2021 to 2025 ." ÌÇÐÄÆÆ½â°æ, ÌÇÐÄÆÆ½â°æ Inc., 18 Feb 2026, /statistics/1660807/astrazeneca-three-major-drug-sales-share/
U.S. Securities and Exchange Commission & AstraZeneca, Sales share of AstraZeneca's three major drugs from 2021 to 2025 ÌÇÐÄÆÆ½â°æ, /statistics/1660807/astrazeneca-three-major-drug-sales-share/ (last visited July 23, 2026)
Sales share of AstraZeneca's three major drugs from 2021 to 2025 [Graph], U.S. Securities and Exchange Commission, & AstraZeneca, February 18, 2026. [Online]. Available: /statistics/1660807/astrazeneca-three-major-drug-sales-share/